Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives
Riccardo Nevola, Angela Villani, Simona Imbriani, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 5, pp. 103-103
Open Access | Times Cited: 10

Showing 10 citing articles:

The relationship between SGLT2 and systemic blood pressure regulation
Priscilla Ahwin, Diana Martínez
Hypertension Research (2024) Vol. 47, Iss. 8, pp. 2094-2103
Open Access | Times Cited: 16
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
Rosalinda Madonna, Filippo Biondi, Mattia Alberti, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116650-116650
Open Access | Times Cited: 5
Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies
Shivangi Dwivedi, Mukesh Singh Sikarwar
Hormone and Metabolic Research (2024)
Closed Access | Times Cited: 4
The Role of SGLT1 in Atrial Fibrillation and Its Relationship with Endothelial-Mesenchymal Transition
Zhi-Hong Ning, Xianding Wang, Huifang Tang, et al.
Biochemical and Biophysical Research Communications (2025) Vol. 748, pp. 151338-151338
Closed Access
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, et al.
Exploration of Medicine (2025)
Open Access
The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview
Loredana N. Ionică, Adina V. Lința, Alina D. Bătrîn, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7711-7711
Open Access | Times Cited: 2
Adverse events and drug–drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure
Claudia Stöllberger, Josef Finsterer, Birke Schneider
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 11, pp. 803-816
Closed Access | Times Cited: 2
Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts
Enrique Sánchez-Muñoz, Juan Antonio Requena-Ibáñez, Juan J. Badimón
Revista Española de Cardiología (English Edition) (2024) Vol. 77, Iss. 7, pp. 510-514
Closed Access
Inhibición dual del SGLT1 y SGLT2: algo más que su suma
Enrique Sánchez-Muñoz, Juan Antonio Requena-Ibáñez, Juan J. Badimón
Revista Española de Cardiología (2024) Vol. 77, Iss. 7, pp. 510-514
Closed Access
The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease
Na Ao, Jian Du, Shi Jin, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 457-467
Closed Access
Page 1

Scroll to top